Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 24381, Saudi Arabia.
Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan.
Cell Mol Biol (Noisy-le-grand). 2022 Jan 2;67(4):289-298. doi: 10.14715/cmb/2021.67.4.32.
Streptococcus pneumoniae is the bacterium that causes pneumococcal disease which often results in pneumonia, meningitis, otitis media, septicemia and sinusitis. Pneumonia, particularly, is a significant cause of worldwide morbidity and a global health burden as well. Treatment often relies on antimicrobials, to which the pathogen is frequently mutating and rendering infective. Consequently, vaccination is the most effective approach in dealing with pneumococcal antimicrobial resistance (AMR). Unfortunately, the current pneumococcal polysaccharide and conjugate vaccines have a narrow serotype coverage. Therefore, the current need for vaccines with a broader serotype coverage cannot be overstated. Pneumococcal Surface Protein A and C are potential vaccine candidate antigens present in over 90% of the strains from clinical isolates as well as laboratory non-encapsulated strains. Pneumococcal Surface Protein A is an active virulent factor that pneumococci use to evade complement-mediated host immune responses and has been shown to elicit immune responses against pneumococcal infections. This review explores the potential utilization of Pneumococcal Surface Protein A to immunize against S. pneumoniae.
肺炎链球菌是引起肺炎球菌病的细菌，常导致肺炎、脑膜炎、中耳炎、败血症和鼻窦炎。肺炎，特别是，是全球发病率的重要原因，也是全球健康负担。治疗通常依赖于抗生素，而病原体经常发生突变并具有传染性。因此，接种疫苗是应对肺炎球菌抗生素耐药性（AMR）的最有效方法。不幸的是，目前的肺炎球菌多糖和结合疫苗的血清型覆盖范围较窄。因此，目前对具有更广泛血清型覆盖范围的疫苗的需求再怎么强调也不为过。肺炎球菌表面蛋白 A 和 C 是潜在的疫苗候选抗原，存在于临床分离株和实验室非囊泡菌株中超过 90%的菌株中。肺炎球菌表面蛋白 A 是一种活跃的毒力因子，肺炎球菌利用它来逃避补体介导的宿主免疫反应，并已被证明能引起针对肺炎球菌感染的免疫反应。这篇综述探讨了利用肺炎球菌表面蛋白 A 来免疫接种 S. pneumoniae 的潜力。
